A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

This is a non-randomized, open-label, multi-site, single-dose, Phase 3 study in approximately 35 adults and pediatric subjects ≥2 and ≤50 years of age with sickle cell disease (SCD). The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) with LentiGlobin BB305 Drug Product for SCD.

NCT: NCT04293185

Locations: University of Minnesota

Link: https://clinicaltrials.gov/ct2/show/NCT04293185?recrs=ad&cond=Sickle+Cell+Anemia&locn=University+of+Minnesota&cntry=US&age=0&draw=2&rank=1